

Andrew Mark Scott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5581203/publications.pdf>

Version: 2024-02-01

107
papers

6,964
citations

101543

36
h-index

60623

81
g-index

109
all docs

109
docs citations

109
times ranked

11712
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy planning of lymphomas: role of metabolic imaging with PET/CT. <i>Annals of Nuclear Medicine</i> , 2022, 36, 162.	2.2	2
2	Automated processing of solid target ⁸⁶ Y using enriched SrO powder. <i>Applied Radiation and Isotopes</i> , 2022, 181, 110052.	1.5	0
3	Radiotheranostics in oncology: current challenges and emerging opportunities. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 534-550.	27.6	92
4	The value of ¹⁸ F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 428-448.	6.4	60
5	Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. <i>Journal of Nuclear Medicine</i> , 2021, 62, 422-430.	5.0	20
6	Neutrophil to lymphocyte ratio predicts glucocorticoid resistance in polymyalgia rheumatica. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 56-62.	1.9	5
7	Radiolabelling and preclinical characterization of ⁸⁹ Zr-Df-radiolabelled bispecific anti-PD-L1/TGF- β RII fusion protein bintrafusp alfa. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3075-3088.	6.4	12
8	[¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	13.7	552
9	Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 93, 37-45.	0.6	2
10	Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival. <i>Lung Cancer</i> , 2021, 153, 35-41.	2.0	7
11	Mediators and clinical treatment for cancer cachexia: a systematic review. <i>JCSM Rapid Communications</i> , 2021, 4, 166-186.	1.6	19
12	Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. <i>Lancet Oncology, The</i> , 2021, 22, 341-350.	10.7	32
13	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021, 65, 103252.	6.1	12
14	Medical imaging and nuclear medicine: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , 2021, 22, e136-e172.	10.7	129
15	GPA33 is expressed on multiple human blood cell types and distinguishes CD4 ⁺ central memory T cells with and without effector function. <i>European Journal of Immunology</i> , 2021, 51, 1377-1389.	2.9	1
16	Global Advancement of Nuclear Medicine: KSNM 60 Years of Achievements. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 149-150.	1.0	0
17	Abstract CT101: Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. , 2021, , .		0
18	The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis. <i>Lancet Oncology, The</i> , 2021, 22, 1301-1311.	10.7	14

#	ARTICLE	IF	CITATIONS
19	Increasing Access to Imaging for Addressing the Global Cancer Epidemic. <i>Radiology</i> , 2021, 301, 543-546.	7.3	9
20	The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity. <i>Journal of Nuclear Medicine</i> , 2021, 62, 755-756.	5.0	4
21	Perspectives on Theranostics and Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1492-1494.	5.0	0
22	Pharmacogenomics in Radionuclide Therapy: Impact on Response to Theranostics. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254995.	5.0	6
23	Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254508.	5.0	19
24	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. <i>Journal of Nuclear Medicine</i> , 2021, 62, 14N-19N.	5.0	0
25	Antibody-Drug Conjugates for Cancer Therapy. <i>Molecules</i> , 2020, 25, 4764.	3.8	187
26	The role and contribution of treatment and imaging modalities in global cervical cancer management: survival estimates from a simulation-based analysis. <i>Lancet Oncology</i> , The, 2020, 21, 1089-1098.	10.7	32
27	Estimating the impact of treatment and imaging modalities on 5-year net survival of 11 cancers in 200 countries: a simulation-based analysis. <i>Lancet Oncology</i> , The, 2020, 21, 1077-1088.	10.7	39
28	First clinical study of a pegylated diabody ¹²⁴ I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , 2020, 10, 11404-11415.	10.0	13
29	Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2117-2125.	4.1	30
30	Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort. <i>Lung Cancer</i> , 2020, 150, 1-8.	2.0	8
31	GPA33: A Marker to Identify Stable Human Regulatory T Cells. <i>Journal of Immunology</i> , 2020, 204, 3139-3148.	0.8	26
32	Imaging of neuroinflammation in adult Niemann-Pick type C disease. <i>Neurology</i> , 2020, 94, e1716-e1725.	1.1	13
33	Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2461-2468.	6.4	22
34	Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1476-1485.	6.4	15
35	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629.	5.0	65
36	Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. <i>Blood</i> , 2020, 136, 43-44.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. <i>ELife</i> , 2020, 9, .	6.0	104
38	Sensitization of Cancers Resistant to HER2 Antibodies. <i>Critical Reviews in Oncogenesis</i> , 2020, 25, 175-207.	0.4	1
39	Automated synthesis of 18F radiolabelled indole containing Oncrasin-like molecules; a comparison of iodonium salts and boronic ester chemistry. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 23.	3.9	0
40	2019 SNMMI Highlights Lecture: Oncology and Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 11N-17N.	5.0	0
41	2019 SNMMI Highlights Lecture: Oncology and Therapy, Part 2. <i>Journal of Nuclear Medicine</i> , 2020, 61, 7N-13N.	5.0	0
42	2020 SNMMI Highlights Lecture: Oncology and Therapy, Part 1. <i>Journal of Nuclear Medicine</i> , 2020, 61, 31N-40N.	5.0	0
43	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019, 21, 106-114.	1.2	84
44	Oncogenic mutations at the EGFR ectodomain structurally converge to remove a steric hindrance on a kinase-coupled cryptic epitope. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10009-10018.	7.1	46
45	Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	32
46	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1221-1227.	5.0	10
47	Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. <i>Theranostics</i> , 2019, 9, 1154-1169.	10.0	32
48	ATIM-23. PRELIMINARY FINDINGS OF A PHASE I SAFETY AND BIOIMAGING TRIAL OF KB004 (IFABOTUZUMAB) IN PATIENTS WITH GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi6-vi6.	1.2	5
49	AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 5332-5332.	1.4	2
50	Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. <i>Blood</i> , 2019, 134, 5328-5328.	1.4	1
51	Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 795-805.	4.1	37
52	Accuracy of Dose Calibrators for ⁶⁸ Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. <i>Journal of Nuclear Medicine</i> , 2018, 59, 636-638.	5.0	31
53	Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. <i>Rheumatology</i> , 2018, 57, 345-353.	1.9	19
54	Molecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 783-791.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling. <i>Nature Medicine</i> , 2018, 24, 463-473.	30.7	120
56	The Impact of ⁶⁸ Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 82-88.	5.0	281
57	Long-Acting Somatostatin Analog Therapy Differentially Alters ⁶⁸ Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions. <i>Journal of Nuclear Medicine</i> , 2018, 59, 223-227.	5.0	48
58	CSIG-25. EPIDERMAL GROWTH FACTOR RECEPTOR EXTRACELLULAR DOMAIN MISSENSE MUTATION A289V AS A DRIVER OF GLIOBLASTOMA INVASION AND PROLIFERATION. <i>Neuro-Oncology</i> , 2018, 20, vi48-vi48.	1.2	0
59	ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414. <i>Neuro-Oncology</i> , 2018, 20, vi24-vi24.	1.2	2
60	Preclinical toxicological assessment of a novel monoclonal antibody targeting human platelet-derived growth factor CC (PDGF-CC) in PDGF-CChum mice. <i>PLoS ONE</i> , 2018, 13, e0200649.	2.5	5
61	Confocal Microscopy Reveals Cell Surface Receptor Aggregation Through Image Correlation Spectroscopy. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	3
62	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2018, 41, 114-121.	3.5	97
63	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1209-1217.	2.3	108
64	Bridging Bioâ€“Nano Science and Cancer Nanomedicine. <i>ACS Nano</i> , 2017, 11, 9594-9613.	14.6	304
65	Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors. <i>Experimental Hematology</i> , 2017, 54, 31-39.	0.4	18
66	Is cholineâ€“based PET imaging still relevant in recurrent prostate cancer?. <i>BJU International</i> , 2017, 120, 303-304.	2.5	1
67	Antibodyâ€“drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 695-707.	27.6	90
68	Evolution of anti-HER2 therapies for cancer treatment. <i>Cancer Treatment Reviews</i> , 2017, 59, 1-21.	7.7	73
69	<i>In Vitro</i> and <i>In Vivo</i> Evaluation of ⁸⁹ Zr-DS-8273a as a Theranostic for Anti-Death Receptor 5 Therapy. <i>Theranostics</i> , 2016, 6, 2225-2234.	10.0	12
70	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 2â€“Current Standards and the Path Toward Global Standardization. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1148-1157.	5.0	26
71	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. <i>Nature Neuroscience</i> , 2016, 19, 798-806.	14.8	82
72	An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth. <i>Journal of Experimental Medicine</i> , 2016, 213, 1741-1757.	8.5	55

#	ARTICLE	IF	CITATIONS
73	Molecular Imaging and Quantitation of EphA2 Expression in Xenograft Models with ⁸⁹ Zr-DS-8895a. <i>Journal of Nuclear Medicine</i> , 2016, 57, 974-980.	5.0	21
74	A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells. <i>PLoS ONE</i> , 2015, 10, e0144559.	2.5	58
75	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1141-1151.	4.1	70
76	Standardization of Administered Activities in Pediatric Nuclear Medicine: A Report of the First Nuclear Medicine Global Initiative Project, Part 1—Statement of the Issue and a Review of Available Resources. <i>Journal of Nuclear Medicine</i> , 2015, 56, 646-651.	5.0	32
77	Structural biology of antibody recognition of carbohydrate epitopes and potential uses for targeted cancer immunotherapies. <i>Molecular Immunology</i> , 2015, 67, 75-88.	2.2	38
78	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1889-1894.	1.5	88
79	Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways. <i>Oncotarget</i> , 2015, 6, 38166-38180.	1.8	14
80	Detection of activated platelets in a mouse model of carotid artery thrombosis with ¹⁸ F-labeled single-chain antibodies. <i>Nuclear Medicine and Biology</i> , 2014, 41, 229-237.	0.6	21
81	¹⁸ F-fluorodeoxyglucose—Positron Emission Tomography/Computed Tomography Aids Staging and Predicts Mortality in Patients With Muscle-invasive Bladder Cancer. <i>Urology</i> , 2014, 83, 393-399.	1.0	41
82	Targeting EphA3 Inhibits Cancer Growth by Disrupting the Tumor Stromal Microenvironment. <i>Cancer Research</i> , 2014, 74, 4470-4481.	0.9	71
83	Radiolabelling and evaluation of a novel sulfoxide as a PET imaging agent for tumor hypoxia. <i>Nuclear Medicine and Biology</i> , 2014, 41, 419-425.	0.6	6
84	In vivo imaging of cellular proliferation in renal cell carcinoma using ¹⁸ F-fluorothymidine PET. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2014, 2, 3-11.	0.1	6
85	Pharmacodynamic analysis of tumour perfusion assessed by ¹⁵ O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , 2012, 2, 31.	2.5	10
86	Antibody therapy of cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 278-287.	28.4	1,861
87	¹¹ C-choline PET scanning is more accurate than biopsy in assessment of localized prostate cancer planned for radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2012, 30, 182-182.	1.6	1
88	A simplified protocol for the automated production of succinimidyl ¹⁸ F-fluorobenzoate on an IBA Synthra module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 671-673.	1.0	22
89	Synthesis of ¹⁸ F-Fluorobenzoyloxy)methyl]-1,4-naphthalenedione from ¹⁸ F-fluorobenzoyloxy)methyl]-1,4-naphthalenedione and ¹⁸ F-fluorobenzoic acid using dicyclohexyl carbodiimide. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2011, 54, 788-794.	1.0	6
90	Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 347-353.	6.4	35

#	ARTICLE	IF	CITATIONS
91	PET Changes Management and Improves Prognostic Stratification in Patients with Recurrent Colorectal Cancer: Results of a Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1451-1457.	5.0	82
92	PET Changes Management and Improves Prognostic Stratification in Patients with Head and Neck Cancer: Results of a Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1593-1600.	5.0	85
93	Targeting Lewis Y-Positive Multiple Myeloma and Acute Myeloid Leukemia with Gene-Modified T Cells Demonstrating Memory Phenotype. <i>Blood</i> , 2008, 112, 3900-3900.	1.4	7
94	A Phase I Biodistribution and Pharmacokinetic Trial of Humanized Monoclonal Antibody Hu3s193 in Patients with Advanced Epithelial Cancers that Express the Lewis-Y Antigen. <i>Clinical Cancer Research</i> , 2007, 13, 3286-3292.	7.0	63
95	Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 451-461.	4.6	274
96	F-18 labelled N,N-bis-haloethylamino-phenylsulfoxides are a new class of compounds for the imaging of hypoxic tissue. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1089-1103.	1.0	11
97	Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. <i>Journal of Nuclear Medicine</i> , 2006, 47, 410-8.	5.0	126
98	Immunological effects of chimeric anti-CD3 monoclonal antibody KM871 in patients with metastatic melanoma. <i>Cancer Immunity</i> , 2005, 5, 3.	3.2	10
99	A Phase I dose-escalation study of sibtrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1639-47.	7.0	268
100	11C labelling of AG957: a potential tyrosine kinase inhibitor radiotracer for PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 157-165.	1.0	7
101	CLINICAL ROLE OF F-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY FOR DETECTION AND MANAGEMENT OF RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 825-830.	0.4	186
102	Targeting properties of an anti-CD16/anti-CD30 bispecific antibody in an in vivo system. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 102-108.	4.2	9
103	Construction, expression and characterisation of a single-chain diabody derived from a humanised anti-Lewis Y cancer targeting antibody using a heat-inducible bacterial secretion vector. <i>Cancer Immunology, Immunotherapy</i> , 2001, 50, 241-250.	4.2	27
104	Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. <i>International Journal of Cancer</i> , 2001, 94, 645-651.	5.1	58
105	Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 177-180.	2.4	38
106	Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. <i>FEBS Journal</i> , 2000, 267, 2505-2515.	0.2	101
107	Antibody-drug conjugates: beyond current approvals and potential future strategies. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 252-277.	0.8	11